<div id="readability-page-1"><p><span>Alto Neuroscience (NYSE:ANRO - Get Free Report)</span> had its target price raised by stock analysts at Chardan Capital  from $15.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Chardan Capital's target price would suggest a potential upside of 80.67% from the company's current price.</p><p>ANRO has been the topic of several other research reports. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Jefferies Financial Group boosted their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, November 12th. Wall Street Zen raised Alto Neuroscience from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. BTIG Research initiated coverage on Alto Neuroscience in a report on Monday, November 17th. They issued a &#34;buy&#34; rating and a $27.00 price objective for the company. Finally, Robert W. Baird upped their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 13th. Six equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $26.33.</p><div><p><span></span><span>Get <strong>Alto Neuroscience</strong> alerts:</span></p></div><p><b>View Our Latest Stock Report on ANRO</b></p><h2>Alto Neuroscience Price Performance</h2><p>ANRO opened at $16.61 on Monday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $20.91. The firm has a 50-day moving average of $14.89 and a 200 day moving average of $7.83. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The firm has a market cap of $515.92 million, a P/E ratio of -7.25 and a beta of 2.78. </p><p>Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14.  On average, research analysts expect that  Alto Neuroscience will post -2.54 EPS for the current year. </p><h2>Institutional Trading of Alto Neuroscience</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can bought a new position in  Alto Neuroscience in the 2nd quarter worth about $25,000.  Ground Swell Capital LLC purchased a new stake in shares of  Alto Neuroscience in the second quarter worth about $27,000.  Vanguard Personalized Indexing Management LLC purchased a new stake in shares of  Alto Neuroscience in the second quarter worth about $33,000.  AlphaCore Capital LLC boosted its position in shares of  Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock valued at $44,000 after acquiring an additional 10,000 shares during the period.  Finally, AQR Capital Management LLC purchased a new position in  Alto Neuroscience during the first quarter valued at approximately $52,000. </p><h2>Alto Neuroscience Company Profile</h2> (Get Free Report)<p>Alto Neuroscience <span>NYSE: ANRO<span></span></span> is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.  </p><p>Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Alto Neuroscience</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Do not delete, read immediately</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax</li><li>First Time Since 2007: All Warnings Active</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFOUk8"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alto Neuroscience Right Now?</h2><p>Before you consider Alto Neuroscience, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.</p><p>While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANRO

<p>Chardan Capital has raised its price target for Alto Neuroscience (NYSE:ANRO) from $15.00 to $30.00, maintaining a "buy" rating. This new target suggests an 80.67% potential upside from the current price. Other analysts have varied opinions, with Weiss Ratings giving a "sell" rating, while Jefferies Financial Group and BTIG Research have set targets of $25.00 and $27.00, respectively. The stock has an average rating of "Moderate Buy" and a consensus price target of $26.33. Alto Neuroscience focuses on precision medicine for neuropsychiatric disorders.</p>

Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00